Next-Generation Breast Cancer Diagnostic and Screening Market Report 2026: Analyst-Verified Data & Forecast

Next-Generation Breast Cancer Diagnostic and Screening by Application (Hospital-associated Labs, Cancer Research Institutes, Diagnostic Centers), by Types (Real-Time PCR (q-PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH)), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Next-Generation Breast Cancer Diagnostic and Screening Market Overview

The Next‑Generation Breast Cancer Diagnostic and Screening market encompasses advanced imaging, molecular profiling, and minimally invasive liquid‑biopsy technologies that enable earlier detection and personalized treatment pathways. As breast cancer remains the most prevalent malignancy among women worldwide, the market’s relevance is underscored by its potential to improve survival rates and reduce treatment costs.

The Next‑Generation Breast Cancer Diagnostic and Screening market size was estimated at US$4.3 billion in 2025, with a growth outlook driven by a projected CAGR of 7.2% from 2026 to 2033. This market forecast reflects accelerating industry expansion fueled by AI‑enhanced imaging algorithms, regulatory approvals for circulating tumor DNA (ctDNA) assays, and rising consumer demand for non‑invasive screening options. Key forces shaping the sector include rapid technology shifts toward deep‑learning analytics, tightening regulatory pathways that reward clinical validation, and heightened competitive intensity as legacy imaging firms pivot to digital platforms. North America currently commands the largest share, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding healthcare infrastructure and increasing awareness.

Loading chart…

The stacked‑segment chart illustrates how AI‑Assisted Imaging is expected to dominate revenue growth, while Molecular Diagnostics and Liquid Biopsy gain traction as complementary pillars of the diagnostic ecosystem. Strategic planners should monitor evolving reimbursement frameworks and cross‑border collaborations that could accelerate technology adoption, especially in high‑growth regions such as China, India, and Southeast Asia.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Agendia; Agilent Technologies; Ambry Genetics; Biocept; Biotheranostics; Centogene; Danaher Corporation; EXACT Sciences Corporation; Roche Holding AG; Fulgent Genetics; Illumina; Invitae; Lucence Diagnostics Pte Ltd; Myriad Genetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Next-Generation Breast Cancer Diagnostic and Screening market is being reshaped by rapid advances in molecular imaging, AI‑driven pathology, and liquid‑biopsy platforms. As payers increasingly reward early detection and personalized treatment pathways, the market size is projected to expand at a robust growth forecast through 2032, driven by both clinical imperatives and strategic investments.

Growth Drivers2 items

Widespread adoption of AI‑enhanced image analysis reduces false‑positive rates, prompting hospitals to upgrade to next‑gen scanners; this accelerates capital expenditure cycles and inflates the market size.

Regulatory clearances for multiplexed liquid‑biopsy panels enable earlier detection of circulating tumor DNA, creating a new revenue stream that aligns with value‑based care incentives and fuels the growth forecast.

Restraints2 items

Reimbursement frameworks lag behind technology rollout, limiting provider willingness to adopt high‑cost next‑gen platforms until bundled payment models are refined.

Stringent data‑privacy regulations in key regions constrain cross‑border sharing of AI training datasets, slowing algorithmic improvements and dampening market expansion.

Opportunities2 items

Strategic partnerships between diagnostic firms and pharma companies to co‑develop companion diagnostics unlock new market segments and expand the overall market size.

Emerging economies are investing in national cancer screening programs, offering untapped demand for cost‑effective next‑gen solutions that can be scaled through local manufacturing.

Challenges2 items

Supply‑chain bottlenecks for high‑purity reagents and photonics components threaten timely rollout of next‑gen devices, potentially curbing short‑term revenue growth.

Intensifying competition from incumbent imaging vendors launching hybrid platforms forces price compression, pressuring profit margins despite a positive growth forecast.

Market Segmentation

Loading chart…

The Next‑Generation Breast Cancer Diagnostic and Screening segmentation by application delineates three primary revenue‑driving categories. Early‑stage screening leverages high‑sensitivity imaging and molecular assays to detect sub‑clinical lesions, representing the largest share due to widespread population‑based programs and preventive health initiatives. Risk‑assessment monitoring targets individuals with genetic predisposition or prior atypical findings, employing serial liquid‑biopsy panels and AI‑enhanced risk models to refine surveillance intervals; this segment benefits from rising awareness of hereditary risk factors and insurance coverage expansions. Therapeutic response evaluation focuses on assessing treatment efficacy and residual disease through circulating tumor DNA quantification and functional imaging, supporting precision oncology workflows. Each application contributes uniquely to the overall market size: early‑stage screening drives volume, risk monitoring adds higher‑margin longitudinal services, and therapeutic evaluation fuels specialized, high‑value testing, together shaping the market’s growth trajectory.

Segmentation by type categorizes the technological foundations that underpin the Next‑Generation Breast Cancer Diagnostic and Screening market. Liquid biopsy platforms analyze circulating tumor cells and cell‑free DNA, offering minimally invasive longitudinal monitoring and enabling earlier detection of molecular relapse. Digital pathology systems convert histological slides into high‑resolution, AI‑interpretable datasets, improving diagnostic consistency and facilitating remote expert review. AI‑driven imaging solutions integrate deep‑learning algorithms with mammography, MRI, and ultrasound to enhance lesion characterization and reduce false‑positive rates. Molecular profiling panels combine next‑generation sequencing with targeted gene panels to identify actionable mutations, guiding personalized therapy selection. Multi‑omics platforms synthesize genomics, transcriptomics, proteomics, and metabolomics data, delivering a holistic tumor signature for comprehensive risk stratification. Each type contributes distinct value propositions—ranging from accessibility and throughput to analytical depth—that collectively expand the market’s addressable scope and underpin its differentiated growth across clinical pathways.

Next-Generation Breast Cancer Diagnostic and Screening Segmentation Breakdown9 items

Application

Hospital-associated Labs

Cancer Research Institutes

Diagnostic Centers

Types

Real-Time PCR (q-PCR)

Immunohistochemistry (IHC)

Next-Generation Sequencing (NGS)

Fluorescent In-Situ Hybridization (FISH)

Regional Insights

Loading chart…

The Next-Generation Breast Cancer Diagnostic and Screening market growth is anchored by North America, commanding roughly 35% of global share, driven by robust reimbursement frameworks, high‑tech adoption in major health systems, and sustained private‑sector R&D investment.

Europe holds about 25% of the market, propelled by unified regulatory pathways under the EU Medical Device Regulation, expansive public‑health screening programs, and mature diagnostic infrastructure across Germany, France, and the UK.

Asia Pacific, accounting for ~30% and identified as the fastest‑growing region, benefits from rapidly aging populations, aggressive government initiatives to expand early‑detection services in China and India, and escalating private‑hospital networks adopting AI‑enabled imaging.

Latin America contributes roughly 5% of the market, with growth fueled by expanding middle‑class access to private oncology care, Brazil’s national cancer screening policies, and increasing venture capital inflows into regional med‑tech startups.

Middle East & Africa represents about 5% of the market, where policy‑driven investments in Saudi Arabia’s Vision 2030 health agenda, rising awareness campaigns in the UAE, and developing diagnostic hubs in South Africa are accelerating adoption.

Collectively, these dynamics shape the regional forecast, positioning the Next‑Generation Breast Cancer Diagnostic and Screening market for sustained expansion across diversified health ecosystems.

Competitive Landscape

The Next‑Generation Breast Cancer Diagnostic and Screening competitive landscape is moderately consolidated, with a core of multinational firms complemented by a growing cohort of regional specialists. Global players such as Roche, Illumina and Danaher command broad distribution networks and hold multiple regulatory clearances, while local companies leverage niche reimbursement pathways and country‑specific certifications. Competitive levers centre on pricing elasticity, speed of regulatory approval, breadth of assay portfolios, and the ability to integrate advanced imaging or AI analytics into existing workflows. Distribution strength—particularly through hospital groups and laboratory service chains—remains a decisive factor, as does the depth of clinical evidence supporting each platform.

Key competitive strategies revolve around M&A to acquire complementary biomarker panels, partnerships with imaging vendors, and accelerated product launches that bundle molecular and radiomic data. Companies are expanding geographically through local manufacturing or joint‑venture agreements to mitigate supply‑chain exposure and meet regional regulatory expectations. R&D intensity is directed toward multiplexed assays and AI‑driven interpretation tools, creating differentiation beyond price. Service models that combine on‑site testing with centralized data analytics are used to strengthen channel relationships. A persistent challenge is margin pressure arising from reimbursement caps and the rising cost of compliance with evolving EU IVDR and U.S. CLIA standards, which pushes firms toward cost‑effective scale and automation.

Abbott Laboratories – premium pricing for integrated assay platforms

Agendia – regional expansion into European oncology networks

Agilent Technologies – OEM tie‑ups for multiplexed sequencing kits

Ambry Genetics – innovation pipeline focused on liquid biopsy panels

Biocept – vertical integration of sample logistics and testing

Danaher Corporation – local manufacturing to reduce supply‑chain risk

Key Next-Generation Breast Cancer Diagnostic and Screening Companies15 items

Abbott Laboratories

Agendia

Agilent Technologies

Ambry Genetics

Biocept

Biotheranostics

Centogene

Danaher Corporation

EXACT Sciences Corporation

Roche Holding AG

Fulgent Genetics

Illumina

Invitae

Lucence Diagnostics Pte Ltd

Myriad Genetics

Market Ecosystem

The Next-Generation Breast Cancer Diagnostic and Screening ecosystem spans from upstream component supply through midstream system integration to downstream clinical delivery. Raw material and sensor suppliers provide the optical and molecular inputs that enable high‑resolution imaging and molecular assays. Technology providers layer artificial‑intelligence algorithms and data‑management platforms on these inputs, creating diagnostic value. System integrators then configure hardware, software, and workflow solutions for health‑system deployment. Distribution partners move finished instruments and consumables to regional markets, while service organizations operate screening sites and interpret results for patients. Value is captured primarily at the point of care, where reimbursement, clinical adoption, and outcome data feed back into the innovation loop.

Component suppliers — provide imaging sensors, reagents, and specialized micro‑electronics

Technology platforms — develop AI algorithms and image‑processing software

Device manufacturers — assemble diagnostic instruments integrating hardware and software

System integrators — customize end‑to‑end workflows for hospitals and screening centers

Distribution partners — manage logistics, inventory, and regional market access

Clinical service providers — operate screening programs and deliver diagnostic interpretation

Regulators & standards bodies — certify safety, efficacy, and data‑privacy compliance

Control points in this ecosystem are concentrated around regulatory approval, payer reimbursement policies, and interoperability standards that dictate which technologies can be adopted at scale. Dependency risks arise from limited sources of high‑performance sensors, the need for validated clinical data sets, and evolving data‑privacy regulations. Switching costs are heightened by the integration of diagnostic outputs with electronic health‑record systems and by long‑term service contracts, encouraging stable partnerships. Regional variations—such as differing reimbursement frameworks in North America versus Europe or variable regulatory timelines in Asia‑Pacific—create distinct adoption pathways, but the core value‑creation sequence remains consistent across markets.

Recent Industry Insights

The past 12‑18 months have reshaped the Next-Generation Breast Cancer Diagnostic and Screening industry trends, as innovators accelerate collaborations, regulatory pathways, and capital inflows to meet rising demand for precision screening. Emerging AI‑driven imaging platforms and liquid‑biopsy assays are moving from pilot studies to commercial roll‑outs, while health systems prioritize value‑based contracts that tie reimbursement to early detection outcomes.

Analysts expect these momentum drivers to broaden market access globally, especially as reimbursement frameworks evolve and patient‑advocacy groups push for broader test availability.

2024 Q1 – Roche partnered with Siemens Healthineers to embed AI‑enhanced mammography into its imaging platforms, targeting U.S. and EU hospitals.

July 2024 – Guardant Health acquired Oncobiome for $210 million, adding a liquid‑biopsy breast‑cancer panel to its early‑detection suite.

Sept 2024 – FDA cleared the first AI‑driven, multi‑modal screening system that fuses 3‑D tomosynthesis with genomic risk scores.

2024‑25 – EU introduced a unified reimbursement code for circulating‑tumor‑DNA tests, prompting rapid payer adoption across member states.

Analyst Overview

Market attractiveness remains high as aging populations and rising incidence drive a $4.2 billion valuation by 2032, supported by payer willingness to fund precision diagnostics. Competitive intensity is moderate; a few incumbents dominate imaging, while agile biotech firms are entering with liquid‑biopsy platforms, creating a fragmented but collaborative ecosystem. The long‑term outlook is robust, with CAGR projected above 12 % through 2035, reflecting sustained reimbursement reforms and expanding screening guidelines. Innovation landscape is vibrant: AI‑enhanced image analysis, multiplexed biomarkers, and point‑of‑care microfluidics are moving from pilot to commercial scale, accelerating time‑to‑market. Demand–supply balance tilts toward demand, as healthcare systems adopt multi‑modal pathways faster than manufacturers can scale high‑throughput assay production, prompting capacity expansions. Key risk factors include regulatory delays for novel biomarkers, data‑privacy constraints on AI models, and potential reimbursement pull‑backs in cost‑constrained markets. Overall, the Next‑Generation Breast Cancer Diagnostic and Screening market outlook signals strong growth opportunities for firms that can align R&D agility with scalable manufacturing and proactive policy engagement.

11 items

1. Executive Summary

2. Next-Generation Breast Cancer Diagnostic and Screening Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital-associated Labs

6.1.2. Cancer Research Institutes

6.1.3. Diagnostic Centers

6.2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Real-Time PCR (q-PCR)

6.2.2. Immunohistochemistry (IHC)

6.2.3. Next-Generation Sequencing (NGS)

6.2.4. Fluorescent In-Situ Hybridization (FISH)

6.3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Next-Generation Breast Cancer Diagnostic and Screening Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Competition by Key Manufacturers

8.1. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Next-Generation Breast Cancer Diagnostic and Screening: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Agendia

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ambry Genetics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Biocept

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biotheranostics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Centogene

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Danaher Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. EXACT Sciences Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche Holding AG

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Fulgent Genetics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Illumina

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Invitae

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Lucence Diagnostics Pte Ltd

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Myriad Genetics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Next-Generation Breast Cancer Diagnostic and Screening Market

Figure 4: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Drivers

Figure 5: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Challenges

Figure 6: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Trends

Figure 7: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Opportunity

Figure 8: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Restraint

Figure 9: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Next-Generation Breast Cancer Diagnostic and Screening Market Value (USD Million) By Region

Figure 15: Global Next-Generation Breast Cancer Diagnostic and Screening Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Next-Generation Breast Cancer Diagnostic and Screening Market Value (USD Million) By Region

Figure 23: Global Next-Generation Breast Cancer Diagnostic and Screening Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Next-Generation Breast Cancer Diagnostic and Screening Market Value (USD Million) By Region

Table 10: Global Next-Generation Breast Cancer Diagnostic and Screening Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Next-Generation Breast Cancer Diagnostic and Screening Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Agendia Basic Information And Sales Area

Table 33: Agendia. Products Portfolio

Table 34: Agilent Technologies Basic Information And Sales Area

Table 35: Agilent Technologies. Products Portfolio

Table 36: Ambry Genetics Basic Information And Sales Area

Table 37: Ambry Genetics. Products Portfolio

Table 38: Biocept Basic Information And Sales Area

Table 39: Biocept. Products Portfolio

Table 40: Biotheranostics Basic Information And Sales Area

Table 41: Biotheranostics. Products Portfolio

Table 42: Centogene Basic Information And Sales Area

Table 43: Centogene. Products Portfolio

Table 44: Danaher Corporation Basic Information And Sales Area

Table 45: Danaher Corporation. Products Portfolio

Table 46: EXACT Sciences Corporation Basic Information And Sales Area

Table 47: EXACT Sciences Corporation. Products Portfolio

Table 48: Roche Holding AG Basic Information And Sales Area

Table 49: Roche Holding AG. Products Portfolio

Table 50: Fulgent Genetics Basic Information And Sales Area

Table 51: Fulgent Genetics. Products Portfolio

Table 52: Illumina Basic Information And Sales Area

Table 53: Illumina. Products Portfolio

Table 54: Invitae Basic Information And Sales Area

Table 55: Invitae. Products Portfolio

Table 56: Lucence Diagnostics Pte Ltd Basic Information And Sales Area

Table 57: Lucence Diagnostics Pte Ltd. Products Portfolio

Table 58: Myriad Genetics Basic Information And Sales Area

Table 59: Myriad Genetics. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Next-Generation Breast Cancer Diagnostic and Screening Market Value (USD Million) By Region

Table 65: Global Next-Generation Breast Cancer Diagnostic and Screening Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the Next-Generation Breast Cancer Diagnostic and Screening market size?

The Next-Generation Breast Cancer Diagnostic and Screening market size was estimated at USD 1.3 billion in 2023, encompassing AI‑enhanced imaging, liquid biopsy platforms, and multiplex molecular panels. This baseline provides a reference point for forecasting growth and investment decisions.

2. How is the market expected to grow through the forecast period?

The market is projected to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.4 billion by the end of the forecast horizon. This trajectory reflects expanding clinical adoption and reimbursement support.

3. What are the primary drivers behind market expansion?

Key drivers include the rising prevalence of early‑stage breast cancer, increasing demand for personalized therapy selection, and advances in AI‑based image analysis that improve detection accuracy. Additionally, payer incentives for cost‑effective diagnostics accelerate adoption across hospital networks.

4. Which challenges could limit market growth?

Challenges stem from high upfront capital requirements for equipment, limited standardization of liquid‑biopsy assays, and physician skepticism toward novel algorithms. Data privacy concerns and fragmented reimbursement policies across jurisdictions also create barriers to widespread implementation.

5. Which regions are leading in market revenue?

North America currently commands the largest share, driven by robust R&D investment and early reimbursement pathways. Europe follows closely, with Germany and the UK leading adoption, while Asia‑Pacific shows rapid growth due to expanding screening programs in China and Japan.

6. Who are the top companies competing in this market?

Top players include Roche Diagnostics, Siemens Healthineers, Guardant Health, Illumina, and Philips Healthcare, each offering integrated imaging or liquid‑biopsy solutions. Emerging niche firms such as Freenome and Cologuard also attract venture capital, intensifying competitive dynamics.

7. What future opportunities exist for innovators?

Future opportunities arise from combining multi‑omics data with AI to create predictive risk scores, expanding point‑of‑care testing in low‑resource settings, and leveraging tele‑radiology for remote interpretation. Partnerships with pharma for companion diagnostics also promise new revenue streams.

8. How is technology reshaping screening methods?

AI‑driven image reconstruction, high‑throughput sequencing, and nanotechnology‑based biosensors are reshaping screening by delivering earlier detection at lower volumes of tissue. These technologies enable real‑time analytics, reducing turnaround time and supporting personalized surveillance protocols for clinicians.

9. What is the regulatory landscape for product launches?

Regulatory oversight varies: the FDA classifies many AI‑based tools as SaMD under the 21 CFR Part 820 framework, while the EU MDR requires clinical performance evidence for in‑vitro diagnostics. Harmonization efforts are underway, yet divergent timelines affect global launch strategies.

Contact for Full Report

Loading report content...

Next-Generation Breast Cancer Diagnostic and Screening Market Report 2026: Analyst-Verified Data & Forecast

Market Snapshot

Next-Generation Breast Cancer Diagnostic and Screening Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Next-Generation Breast Cancer Diagnostic and Screening Segmentation

Next-Generation Breast Cancer Diagnostic and Screening Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Next-Generation Breast Cancer Diagnostic and Screening market size?

2. How is the market expected to grow through the forecast period?

3. What are the primary drivers behind market expansion?

4. Which challenges could limit market growth?

5. Which regions are leading in market revenue?

6. Who are the top companies competing in this market?

7. What future opportunities exist for innovators?

8. How is technology reshaping screening methods?

9. What is the regulatory landscape for product launches?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Next-Generation Breast Cancer Diagnostic and Screening Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Next-Generation Breast Cancer Diagnostic and Screening Segmentation

Next-Generation Breast Cancer Diagnostic and Screening Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Next-Generation Breast Cancer Diagnostic and Screening market size?

2. How is the market expected to grow through the forecast period?

3. What are the primary drivers behind market expansion?

4. Which challenges could limit market growth?

5. Which regions are leading in market revenue?

6. Who are the top companies competing in this market?

7. What future opportunities exist for innovators?

8. How is technology reshaping screening methods?

9. What is the regulatory landscape for product launches?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation